Company / Capital Expenditures
Biogen Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$153.8M
FY2025
5-year range
$153.7M / $277.0M
FY2021-FY2025
Trend
+0.1%
vs FY2024
Sector context
#19 of 192
Health Care
What the data says
Among 192 Health Care companies, Biogen is in the top 10% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $154M in FY2024 to $867M in FY2017.
Based on SEC 10-K filings.
$154M in FY2025 with a 5-year CAGR of -18.4%. Top quartile in the Health Care sector.
Declined from $277M to $154M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- -18.4%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 192This company $153.8M Sector average $118.6M
▼
+29.7% above sector average
Key checks
Key Insights
- 5-year CAGR of -18.4%, indicating a declining trend.
- In FY2025, capital expenditures increased 0.1% year-over-year.
- Ranks #19 out of 192 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $153.8M | +0.1% |
| FY2024 | $153.7M | -44.5% |
| FY2023 | $277.0M | +15.3% |
| FY2022 | $240.3M | -6.9% |
| FY2021 | $258.1M | -39.2% |
| FY2020 | $424.8M | -17.4% |
| FY2019 | $514.5M | -33.2% |
| FY2018 | $770.6M | -11.2% |
| FY2017 | $867.4M | +40.8% |
| FY2016 | $616.1M | -4.2% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026